author-photo

Lillian Sams

Eli Lilly and Company

11

Papers

759

Citations

Citation Trend

Filter By

Papers (8) Sort By

Journal Conference Others

Abstract 2187: Tryptophan Metabolism Plays a Central Role in Immunosuppression

2019 Cancer Research
Show All
- Source
- Cite
- Save
Citations (1)
Abstract 5245: Identification and characterization of the IDO1 inhibitor LY3381916

2018 Cancer Research
Show All
- Source
- Cite
- Save
Citations (7)
A phase I trial of LY2584702 tosylate, a p70 S6 kinase inhibitor, in patients with advanced solid tumours

2014 European Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (36)
Abstract 352: Preclinical evaluation of LYS6K1, a novel, highly selective, orally bioavailable inhibitor of p70 S6 kinase currently in phase I clinical trials for cancer

2010 Cancer Research
Show All
- Source
- Cite
- Save
Citations (1)
62 Pre-clinical evaluation of LYS6KAKT1, a novel, highly selective, orally bioavailable dual inhibitor of p70 S6 Kinase and AKT currently in phase I clinical trials for cancer

2010 Ejc Supplements
Show All
- Source
- Cite
- Save
Citations (0)
Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity

2007 Journal of Clinical Investigation
Show All
- Source
- Cite
- Save
Citations (312)
Development of medium throughput cell-based ELISAs to quantitate the activity of PI3K-AKT pathway inhibitors

2007 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
The Protein Kinase Cβ–Selective Inhibitor, Enzastaurin (LY317615.HCl), Suppresses Signaling through the AKT Pathway, Induces Apoptosis, and Suppresses Growth of Human Colon Cancer and Glioblastoma Xenografts

2005 Cancer Research
Show All
- Source
- Cite
- Save
Citations (392)